Could a daily pill boost growth in kids with hypochondroplasia?
NCT ID NCT06873035
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times
Summary
This study tests an oral drug called infigratinib in children with hypochondroplasia, a condition that causes short stature. The trial has two parts: first, all children receive the drug to see if it safely increases their growth rate; then, some will switch to a placebo to confirm the effect. Up to 24 children aged 3 to 11 will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- infigratinib (oral drug)
- What this could lead to
- If successful, this could provide a treatment option to improve growth in children with hypochondroplasia.
- What could go wrong
- This is an early-to-mid-stage trial with only 24 participants. The drug may not work as hoped, and side effects could require dose changes or stopping treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOCHONDROPLASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Astrid Lindgren Children's Hospital
Solna, Sweden, 17164, Sweden
-
Centre Hospitalier Universitaire (CHU) de Toulouse - Hôpital des Enfants
Toulouse, France, 31059, France
-
Children's Hospital of Eastern Ontario Research Institute
Ottawa, Ontario, K1H 8L1, Canada
-
Children's National Hospital
Washington D.C., District of Columbia, 20010, United States
-
Childrens Hospital Colorado
Aurora, Colorado, 80045, United States
-
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229, United States
-
Glasgow Clinical Research Facility, Queen Elizabeth University Hospital
Glasgow, Scotland, G51 4TF, United Kingdom
-
Haukeland University Hospital
Bergen, Norway, 5021, Norway
-
Hospital Pediátrico de Coimbra
Coimbra, Portugal, 3000-602, Portugal
-
Hôpital Femme Mère Enfant
Bron, France, 69677, France
-
Hôpital Universitaire Necker-Enfants Malades
Paris, France, 75015, France
-
Johns Hopkins School of Medicine
Baltimore, Maryland, 21287, United States
-
KK Women's and Children's Hospital
Singapore, Singapore, 229899, Singapore
-
London Health Services Centre - Children's Hospital of Western Ontario
London, Ontario, N6C 2R5, Canada
-
Manchester University
Manchester, England, M13 9WL, United Kingdom
-
Murdoch Children's Research Institute - The Royal Children's Hospital Melbourne
Parkville, Victoria, 3052, Australia
-
Paediatric Clinical Research Unit at Oslo University Hospital
Oslo, Norway, 0372, Norway
-
Sheffield Children's Hospital
Sheffield, England, S10 2TH, United Kingdom
-
UCSF Benioff Children's Hospital
Oakland, California, 94609, United States
-
Unidad de Cirugía Artroscopica, Hopsital MIKS
Vitoria-Gasteiz, Spain, 01010, Spain
-
University of Missouri
Columbia, Missouri, 65201, United States
-
University of Wisconsin Madison - Waisman Center Bone Dysplasia Clinic
Madison, Wisconsin, 53705, United States
-
Université de Montréal - Centre Hospitalier Universitaire Sainte-Justine
Montreal, Quebec, H3T 1C5, Canada
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New hope for babies with rare dwarfism: daily shot may boost growth
- Massive database aims to unlock secrets of facial birth defects
- Hope for kids with rare bone disorder: new drug shows promise in Long-Term trial
- Wearable tech tracks movement in rare bone disorders
- New study tracks growth in kids with rare bone disorder
- New drug aims to help short-statured children grow taller